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1. INTRODUCTION 
Analysis may be defined as the science and art of determining the composition 
of materials in terms of the elements or compounds contained in them. In fact, 
analytical chemistry is the science of chemical identification and determination of the 
composition (atomic, molecular) of substances, materials and their chemical 
structure1.  
Chemical compounds and metallic ions are the basic building blocks of all 
biological structures and processes which are the basis of life. Some of these naturally 
occurring compounds and ions (endogenous species) are present only in very small 
amounts in specific regions of the body, while others such as peptides, proteins, 
carbohydrates, lipids and nucleic acids are found in all parts of the body. The main 
object of analytical chemistry is to develop scientifically substantiated methods that 
allow the qualitative and quantitative evaluation of materials with certain accuracy. 
Analytical chemistry derives its principles from various branches of science like 
chemistry, physics, microbiology, nuclear science and electronics. This method 
provides information about the relative amount of one or more of these components. 
According to WHO, a drug may be defined as any substance or product that is 
used or intended to be used for modifying or exploring physiochemical systems or 
pathophysiological stages for the benefit of the patient. In today’s world, drugs have 
become an inevitable part of one’s life. We use drugs almost every single day. The 
quality of the drug is the most essential feature which directly affects the life of the 
customer. The quality of any product can be judged by only analyzing it. This 
investigative process is a part of science which is called as analysis. Analytical 
Chapter - 1                                                                                                  Introduction 
 
Dept. of Pharmaceutical Analysis           2         JKKMMRF College of Pharmacy 
 
 
 
chemistry is the science of obtaining, processing and communicating information 
about the composition and structure of matter. 
Every country has legislation on bulk drugs and their pharmaceutical 
formulations that sets standards and obligatory quality indices for them. These 
regulations are presented in separate articles relating to individual drugs and are 
published in the form of book called “Pharmacopoeia” (e.g. IP, USP, and BP). 
Quantitative chemical analysis is an important tool to assure that the raw material 
used and the intermediate products meet the required specifications. Every year 
number of drugs is introduced into the market. Also quality is important in every 
product or service, but it is vital in medicines as it involves life. 
There is a time lag from the date of introduction of a drug into the market to 
the date of its inclusion in pharmacopoeias. This happens because of the possible 
uncertainties in the continuous and wider usage of these drugs, report of new 
toxicities and development of patient resistance and introduction of better drugs by 
the competitors. Under these conditions standard and analytical procedures for these 
drugs may not be available in Pharmacopoeias. In instrumental analysis, a physical 
property of the substance is measured to determine its chemical composition. 
Pharmaceutical analysis comprises those procedures necessary to determine the 
identity, strength, quality and purity of substances of therapeutic importance2. 
 Pharmaceutical analysis deals not only with medicaments (drugs and their 
formulations) but also with their precursors i.e. with the raw material on which degree 
of purity and quality of medicament depends. The quality of the drug is determined 
after establishing its authenticity by testing its purity and the quality of pure substance 
in the drug and its formulations. 
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Quality control is a concept which strives to produce a perfect product by 
series of measures designed to prevent and eliminate errors at different stages of 
production. The decision to release or reject a product is based on one or more type of 
control action. With the growth of pharmaceutical industry during last several years, 
there has been rapid progress in the field of pharmaceutical analysis involving 
complex instrumentation. Providing simple analytical procedure for complex 
formulation is a matter of most importance. So, it becomes necessary to develop new 
analytical methods for such drugs. In brief the reasons for the development of newer 
methods of drugs analysis are 
The drug or drug combination may not be official in any pharmacopoeias. 
• A proper analytical procedure for the drug may not be available in the 
literature due to Patent regulations. 
• Analytical methods for a drug in combination with other drugs may not be 
available. 
1.1 DIFFERENT METHODS OF ANALYSIS3 
 The following techniques are available for separation and analysis of 
components of interest. 
 Spectral methods 
The spectral techniques are used to measure electromagnetic radiation which 
is either absorbed or emitted by the sample. 
E.g. UV-Visible spectroscopy, IR spectroscopy, NMR, ESR spectroscopy, 
Flame photometryFluorimetry. 
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 Electro analytical methods 
Electro analytical methods involved in the measurement of current voltage or 
resistanceas a property of concentration of the component in solution mixture. E.g. 
Potentiometry, Conductometry, Amperometry. 
 Chromatographic methods 
Chromatography is a technique in which chemicals in solutions travel down 
columns or over surface by means of liquids or gases and are separated from each 
other due to their molecular characteristics. 
E.g. Paper chromatography, thin layer chromatography (TLC), High 
performance thin layer chromatography (HPTLC), High performance liquid 
chromatography (HPLC), Gas chromatography (GC). 
 Miscellaneous Techniques 
Mass Spectrometry, Thermal Analysis. 
• Hyphenated Techniques 
GC-MS (Gas Chromatography – Mass Spectrometry), LC-MS (Liquid 
Chromatography – Mass Spectrometry), ICP-MS (Inductivity Coupled Plasma- Mass 
Spectrometry), GC-IR (Gas Chromatography – Infrared Spectroscopy), MS-MS 
(Mass Spectrometry – Mass Spectrometry).Analytical techniques that are generally 
used for drug analysis also include Analytical methods for the quantitation of the drug 
in biological fluids may not be available. 
The existing analytical procedures may require expensive reagents and 
solvents. It may also involve cumbersome extraction and separation procedures and 
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these may not be reliable. biological and microbiological methods, radioactive 
methods and physical methods etc. are mentioned in Table 1.1. 
Table 1.1: Summary of Hyphenated separation techniques4 
 Separation 
technique Hyphenated mode   
   
Liquid chromate 
graphy  Liquid chromatography-mass spectrometry(LC/MS) 
 
  Liquid chromatography-Fourier-transform infrared  
  Spectrometry(LC-FTIR)   
  Liquid chromatography-nuclear magnetic resonance 
  spectroscopy(LC/NMR)   
  Liquid   chromatography-inductively   coupled   plasma   mass 
  spectrometry(LC-ICPMS)   
    
Gas 
chromat
ography 
 
Gas chromatography-mass spectrometry(GC/MS) 
 
  Gas chromatography-Fourier-transform infrared(GC-FTIR) 
  Gas chromatography-FTIR-MS(GC-FTIR-MS)  
   
Capillary 
electrophoresis Capillary electrophoresis-mass spectrometry(CE/MS) 
 
  Capillary electrophoresis- nuclear magnetic resonance  
  spectroscopy(CE/NMR)   
  Capillary electrophoresis-surface enhanced Raman spectrometry 
  (TLC-SERS)   
   
Thin layer Thin layer chromatography- mass spectrometry(TLC/MS) 
chromatography(T
LC) Thin   layer   chromatography-   surface   enhanced   Raman 
  spectrometry(TLC-SERS)   
   
Superfic
ial fluid Superficial fluid extraction-capillary gas chromatography-mass 
chromat
ography/ spectrometry(SFE-CGC-MS)   
extractio
n(SFC/S
FE)  Superficial fluid-Fourier-transform infrared(SFC-FTIR) 
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1.2 INTRODUCTION TO HPLC1 
HPLC is also called as high pressure liquid chromatography since high pressure is 
used to increase the flow rate and efficient separation by forcing the mobile phase 
through at much higher rate .The pressure is applied using a pumping system. The 
development of HPLC from classical column chromatography can be attributed to the 
development of smaller particle size .Smaller particle size is important since they offer 
more surface area over the conventional large particle sizes. The HPLC is the method 
of choice in the field of analytical chemistry, since this method is specific, robust, 
linear, precise and accurate and the limit of detection is low and also it offers the 
following advantages. 
• Improved resolution of separated substances column packing with very small 
(3,5 and 10 µm) particles Faster separation times (minutes) 
• Sensitivity 
• Reproducibility 
• Continuous flow detectors capable of handling small 
flow rates Easy sample recovery, handling and 
maintenance. 
1.2. Types of HPLC Techniques5 
1.2.1 Based on Modes of Chromatography 
These distinctions are based on relative polarities of stationary and mobile 
phases 
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• Reverse phase chromatography:In this the stationary phase is non-polar 
and mobile phase is polar. In this technique the polar compounds are 
eluted first andnon polar compounds are retained in the column and eluted 
slowly. Therefore it is widely used technique. 
•
 Normal phase chromatography: In this the stationary phase is polar and 
mobile phase is non-polar. In this technique least polar compounds travel 
faster and are eluted first where as the polar compounds are retained in the 
column for longer time and eluted.4 
1.2.2 Based on Principle of Separation 
• Liquid/solid chromatography (Adsorption):LSC, also called adsorption 
chromatography,the principle involved in this technique is adsorption of the 
components onto stationary phase when the sample solution is dissolved in 
mobile phase and passed through a column of stationary phase.The basis for 
separation is the selective adsorption of polar compounds; analytes that are 
more polar will be attracted more strongly to the active silica gel sites. The 
solvent strength of the mobile phase determines the rate at which adsorbed 
analytes are desorbed and elute. It is widely used for separation of isomers and 
classes of compounds differing in polarity and number of functional groups. It 
works best with compounds that have relatively low or intermediate polarity. 
• Liquid/Liquid chromatography (Partition Chromatography):LLC, also 
called partition chromatography, involves a solid support, usually silica gel or 
kieselguhr, mechanically coated with a film of an organic liquid. A typical 
system for NP LLC column is coated with ß, ß’-oxy dipropionitrile and a 
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nonpolar solvent like hexane as the mobile phase. Analytes are separated 
bypartitioning between the two phases as in solvent extraction. Components 
more soluble in the stationary liquid move more slowly and elute later. 
• Ion exchange: In this the components are separated by exchange of ions 
between an ion exchange resin stationary phase and a mobile electrolyte 
phase. A cation exchange resin is used for the separation of cations and anion 
exchange resin is used to separate a mixture of anions. 
• Size exclusion:In this type, the components of sample are separated according 
to their molecular sizes by using different gels (polyvinyl acetate gel, agarose 
gel).ex: separation of proteins, polysaccharides, enzymes and synthetic 
polymers. 
• Chiral chromatography: In this type of chromatography optical isomers are 
separated by using chiral stationary phase. 
• Affinity chromatography: In this type, the components are separated by an 
equilibrium between a macromolecular and a small molecule for which it has 
a high biological specificity and hence affinity. 
1.2.3 Based on elution technique6 
• Isocratic separation: In this technique, the same mobile phase 
combination is used throughout the process of separation. The same 
polarity or elution strength is maintained throughout the process. 
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• Gradient separation: In this technique, a mobile phase combination of 
lower polarity or elution strength is followed by gradually increasing 
polarity or elution strength. 
1.2.4 Based on the scale of operation 
• Analytical HPLC:Where only analysis of samples are done. Recovery of 
samples for reusing is normally not done, since the sample used is very 
low. Ex: µg quantities. 
• Preparative HPLC: Where the individual fractions of pure compounds 
can be collected using fraction collector. The collected samples are reused. 
Ex: separation of few grams of mixtures by HPLC. 
1.2.5.Based on type of analysis 
• Qualitative analysis: Which is used to identify the compound detect the 
presence of impurities to find out the number of components. This is done 
by using retention time values. 
• Quantitative analysis:This is done to determine the quantity of individual 
or several components of mixture. This is done by comparing the peak 
area of the standard and sample. 
1.3. INSTRUMENTATION OF HPLC7 
The basic liquid chromatograph consists of six basic units. The mobile phase 
supply system, the pump and programmer, the sample valve, the column, the detector 
and finally a means of presenting and processing the results. 
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Mobile phase (solvent) reservoirs and solvent degassing 
The mobile phase supply system consists of number of reservoirs (200mL to 
1,000mL in capacity). They are usually constructed of glass or stainless steel 
materials which are chemically resistant to mobile phase. 
Mobile phase 
Mobile phases in HPLC are usually mixtures of two or more individual 
solvents. The usual approach is to choose what appears to be the most appropriate 
column, and then to design mobile phase that will optimize the retention and 
selectivity of the system. The two most critical parameters for nonionic mobile phases 
are strength and selectivity. 
 
Figure 1.1.Compnents of HPLC Instrument block diagram. 
• Mobile phase preparation 
Mobile phases must be prepared from high purity solvents, including water 
that must be highly purified. Mobile phases must be filtered through ≤1 µm pore size 
filters and be degassed before use. 
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• Degassing of solvents 
Many solvents and solvent mixtures (particularly aqueous mixtures) contain 
significant amounts of dissolved nitrogen and oxygen from the air. These gasses can 
form bubbles in the chromatographic system that cause both serious detector noise 
and loss of column efficiency. These dissolved gases in solvent can be removed by 
the process of degassing. Every solvent must be degassed before introduction into 
pump as it alter the resolution of column and interfere with monitoring of the column 
effluent.  
Degassing is done in many ways: 
 By warming the solvents 
 By stirring vigorously with a magnetic stirrer 
 By subjecting to vaccum filtration 
 By ultra sonication (using ultrasonicator) 
 By bubbling He gas through the solvent reservoir. 
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Table 1.2:Physical properties of common HPLC solvents8. 
Solvent MW BP RI UVCut- Density Viscosity 
Dielectric 
Constant 
   
(25oC) off(nm) g/mL(25oC) (25oC)  
        
Acetonitrile 41.0 82 1.342 190 0.787 0.358 38.8 
Dioxane 88.1 101 1.420 215 1.034 1.26 2.21 
Ethanol 46.1 78 1.359 205 0.789 1.19 24.5 
Ethylacetate 88.1 77 1.372 256 0.901 0.450 6.02 
Methanol 32.0 65 1.326 205 0.792 0.584 32.7 
CH2Cl2 84.9 40 1.424 233 1.326 0.44 8.93 
Isopropanol 60.1 82 1.375 205 0.785 2.39 19.9 
n-propanol 60.1 97 1.383 205 0.804 2.20 20.3 
THF 72.1 66 1.404 210 0.889 0.51 7.58 
Water 18.0 100 1.333 170 0.998 1.00 78.5 
        
 
1.3.2 Pumping systems 
The pumping system is one of the most important features of an HPLC 
system. There is a high resistance to solvent flow due to the narrow columns 
packed with small particles and high pressures are therefore required to achieve 
satisfactory flow rate. The main requirements of pumping systems are: 
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• Generation of pressures up to 6000 psi.  
• Pulse free output 
• Flow rates ranging from 0.01 to 10mL/min 
• Flow control and flow reproducibility of ± 0.5% 
• Corrosion resistant components (seals of Teflon and stainless steel)  
• Should be easy to dismantle and repair. 
There are three basic types of pumps in common use9. 
1. Reciprocating pumps. 
2. Displacement pumps or syringe pumps. 
3. Pneumatic pumps or constant pressure pumps. 
1.3.3 Sample introduction system 
Injection ports are of two basic types, 
The sample is injected directly into the column. 
The sample is deposited before the column inlet and then swept by a valving action 
into the column by the mobile phase. 
Injectors should provide the possibility of injecting the liquid sample within the range 
of 0.1 to 100 mL of volume with high reproducibility and under high pressure (up to 
the 4000psi).They should also produce minimum band broadening and minimize 
possible flow disturbances. The most useful and widely used sampling device for 
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modern LC is the micro sampling injector valve. With these sampling valves, samples 
can be introduced reproducibly into pressurized columns without significant 
interruption of flow, even at elevated temperatures. High-performance valves provide 
extra column band-broadening characteristics comparable or superior to that of 
syringe injection. 
1.3.4 Columns 
Typical analytical columns are 10, 15 and 25 cm in length and are fitted with 
extremely small diameter (3, 5 or 10µm) particles. The internal diameter of the 
columns is usually 4 or 4.6 mm; this is considered the best compromise among 
sample capacity, mobile phase consumption, speed and resolution. Preparative 
columns are of larger diameter. Packing of the column tubing with the small diameter 
particles requires high skill and specialized equipment. For this reason, it is generally 
recommended that the most experienced chromatographers purchase prepacked 
columns, since it is difficult to match the high performance of professionally packed 
LC columns without a large investment in time and equipment. The column can be 
classified based on the material bonded to the silica packed surface such as C4, C8, 
C18, phenyl, chiral, cyanomicrobore columns (1mm to 100cm), U shaped and coiled 
columns are available. Guard columns are used before the analytical column to 
increase the life of analytical columns by  retaining non eluted components and 
particulate matter. 
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Table 1.3: Column Selection Flow Chart10. 
Sample LC mode   Column choice   
   
Basic or acidic Reverse   Phase-ion   pair C18, C8, C6, C4, C2, TMS, 
 (allows neutral and charged CN, amino (not for 
 Compounds To be carbonyl compounds), 
 simultaneously analyzed)  phenyl,  Hamilton  PRP-1 
    (pH 1-13).   
     
Ionisable Ion Exchange 
  
Strong cations exchange, 
 Anionic, cationic   Strong anion exchange. 
     
Neutral a)Normal phase 
  
a)Increasing the polarity of 
    bonded phases diol, CN, 
 b)Reverse phase   NH2, silica alumina  
    b) C18, C8, phenyl, C2. 
         
 
• Column Thermostats 
Control of column temperature is important in liquid chromatography. The 
effect of temperature on retention times and reproducibility is quite significant, 
especially when using the reverse phase models. 
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1.3.5 Detectors11 
Optical detectors are most frequently used. These detectors pass a beam of 
light through the flowing column effluent as it passes through a low volume (~ 
10mL) flow cell. The most commonly used detector in LC is the ultraviolet 
absorption detector. A variable wavelength detector of this type, capable of 
monitoring from 190 to 460-600 nm, will be found suitable for the detection of the 
majority samples. 
Other types of Detectors: 
 UV detector 
 Refractive index detector  
 Flourimetric detector 
 Conductivity detector 
 Amperometric detector 
 Photodiode array detector (PDA detector). 
1.3.6 Data handling 
Data handling in chromatography now ranges from a simple pen recorder to 
complicated computer integration and computerized data handling systems. Several 
manufacturers today offered microprocessor controlled chromatographs. Thus the 
solvent delivery system, injector, oven, detector, fraction collector and data reduction 
can be carried under the control of a central microprocessor with the capability to 
program sequential parameters. 
Chapter - 1                                                                                                  Introduction 
 
Dept. of Pharmaceutical Analysis           17         JKKMMRF College of Pharmacy 
 
 
 
1.4. CHROMATOGRAPHIC PARAMETERS13 
1.4.1Capacity factor (k1) 
The capacity factor is a measure of the degree of retention of an analyte 
relative to an un-retained peak. It is affected by solvent composition, separation, 
aging and temperature of separation. 
 
Where, tR= retention time for the sample peak. 
t0=retention time for the unretained peak. 
The peak should be well-resolved from other peaks and the void volume. 
Generally the value of k' is > 2. 
1.4.2Resolution (Rs) 
Resolution is ability of a column to separate Chromatographic peaks. 
Resolution can be improved by increasing column length, decreasing particle size, 
increasing temperature, changing the eluent or stationary phase. 
 
 
 
Fig. 1.2 :Resolution of peaks 
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Where, 
tR1,tR2 are retention times of the first and second adjacent bands. 
tW1and tW2are baseline at bandwidth of the peaks for reliable quantitationwell-
separated peaks are essential for quantitation. 
Rsof> 2 between the peak of interest and the closest potential interfering peak 
(impurity, excipient, degradation product, internal standard, etc.) are desirable. 
1.4.3.Theoretical plate number / Efficiency (N)12 
A measure of peak band spreading determined by various methods, some of 
which are sensitive to peak asymmetry. Smaller the band spread higher the theoretical 
plate indicates good column and system performance. A theoretical plate is an 
imaginary or hypothetical unit of a column where equilibrium has been established 
between stationary phase and mobile phase. Theoretical plate number is a measure of 
column efficiency that is, how many peaks can be located per unit run-time of the 
Chromatogram. 
  
Where t =retention time for the sample peak,  
wb= peak width. 
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N is fairly constant for each peak on a Chromatogram with a fixed set of 
operatingconditions. H (height) or HETP (height equivalent of a theoretical plate) 
measures the column efficiency per unit length (L) of the column. Parameters which 
can affect N or H include peak position, particle size in column, flow rate of mobile 
phase, column temperature, viscosity of mobile phase, and molecular weight of the 
analyte.The theoretical plate number depends on elution time but in general should be 
> 2000. 
1.4.4 Tailing factor (T) or Asymmetry factor (AF)14 
It is a measure of the symmetry of a peak. 
 
 
 
 
 
Fig. 1.3: Peak Asymmetry 
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Where, W= peak width at 5 % height, 
         f = distance from peak front to apex point at 5% height. 
The accuracy of quantitation decreases with increase in peak tailing because 
of the difficulties encountered by the integrator in determining where/when the peak 
ends and hence the calculation of the area under the peak. 
1.5. METHOD DEVELOPMENT AND VALIDATION13 
1.5.1 Introduction to HPLC Method Development 
A good method development strategy should require only as many experimental runs 
as are necessary to achieve the desired final result .it should be simple as possible,yet 
it should allow the use of sophisticated tools such as computer modeling. 
• Nature of sample 
Before beginning of method development, we need to review about the 
sample, in order to define goals of separation. The kinds of sample related 
information that can be important are: 
The various kinds of sample related information that may be important for method 
development was summarized in Table 1.4. 
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Table .1.4:Information Concerning Sample15 
 
 
S.NO Sample requirements 
  
1. Number of compounds present 
  
2. Chemical structures 
  
3. Molecular weights of compounds 
  
4. pKa values of compounds 
  
5. UV spectra of compounds 
  
6. Concentration range of compounds in samples of interest 
 
7. Sample solubility 
 
• Method requirements 
The goals of the analytical method that need to be developed are considered. The 
detection limits, selectivity, linearity, range, accuracy and precision are defined. 
• Separation goals 
       The goals of HPLC separation need to be specified clearly, which include: 
 The use of HPLC to isolate purified sample components for spectral 
identification or quantitative analysis 
 It may be necessary to separate all degradants or impurities from a product 
for reliable content assay or not 
 In quantitative analysis, the required levels of accuracy and precision 
should be known (a precision of 1 to 2 % is usually achievable) 
 Whether a single HPLC procedure is sufficient for raw material or one or 
more different procedures are desired for formulations 
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 When the number of samples for analysis at one time is greater than 10, a 
run time of less than 20 minutes often will be important. 
 Knowledge on the desired HPLC equipment, HPLC experience and 
academic training do the operators have? 
• Literature search and prior methodology 
The information related to the analyte is surveyed for synthesis, physical and 
chemical properties, solubility and relevant analytical methods. Books, periodicals 
and USP/NF, and publications are reviewed. 
• Choosing a method 
a) Using the information in the literatures, methodology is adapted. The methods are 
modified wherever necessary. Sometimes it is necessary to acquire additional 
instrumentation to reproduce, modify, improve or validate existing methods for 
analytes. 
b) If there are no prior methods for the analyte in the literature, from analogy, the 
compounds that are similar in structure and chemical properties are investigated 
and are worked out. There is usually one compound for which analytical method 
already exist that is similar to the analyte of interest. 
• Instrumental setup and initial studies 
a) The required instrumentation is setup installation, operational and performance 
qualifications of instrumentation verified by using laboratory standard operating 
procedures. 
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b) Always new solvents, filters are used, for example, method development is never 
started, on a HPLC column that has been used earlier. 
c) The analyte standard in a suitable injection/introduction solution and in known 
concentrations and solvents are prepared. It is important to start with an authentic, 
known standard rather than with a complex sample matrix. If the sample is 
extremely close to the standard (ex: bulk drug) then it is possible to start work 
with the actual sample. 
d) Analysis is done using analytical conditions described in the existing literature. 
• Optimization 
During optimization one parameter is changed at a time and set of conditions 
are isolated, rather than using a trial and error approach. Work has been done from an 
organized methodical plan and every step is documented (in lab notebook) in case of 
dead ends.Reversed-Phase HPLC offers multiple parameters for optimizing a 
separation.  
To plan separation by RP-HPLC, the analyst must select both a stationary 
phase and a mobile phase appropriate to the analyte under investigation. In addition 
the analyst must identify chromatographic conditions that will maintain the sharpness 
of analyte bands as the sample moves through the stationary phase column to the 
detector. The first attempt at optimization of separation requires selection of a 
promising set of conditions. 
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To optimize the solvent strength, one approach is to begin with a mobile phase 
that is probably too strong and reduce solvent strength to increase k' (capacity factor, 
is the measure of retention) between successive runs. When all the peaks fit within the 
range 0.5< k' < 20, the mobile phase is near optimum from the standpoint of solvent 
strength. The solvent properties are useful when it comes to selecting one or more 
solvents.  
Table 1.5. Shows preferred experimental conditions for the initial HPLC separation16. 
Separation Variable Preferred Initial Choice 
Column    
Dimensions(length,ID)  15 × 0.46 cm 
Particle size  5 µm a 
Stationary phase  C8 or C18 
Mobile phase   
Solvents A and B  Buffer – acetonitrile 
%B   80-100 % b 
Buffer (compound, PH, 25Mmpotassium phosphate, 
concentration)  2.0 < pH < 3.0 c 
Additives (eg., amine Do not use initially 
modifiers, ion pair reagents)  
Flow rate   1.5 -2.0 mL/min 
Temperature  35-45 0C 
Sample size   
Volume   <25 µL 
Weight   <100 µg 
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• 3.5  m particles are an alternative, using a 7.5 cm column. 
• For an initial isocratic run; an initial gradient run is preferred. 
• No buffer required for neutral samples; for pH <2.5, pH-stable columns recommended. 
Once the solvent strength has been properly adjusted for the sample, the next 
selection parameter that can be explored is α (band spacing). In many cases, it is 
possible to obtain a satisfactory separation simply by varying solvent strength. This is 
usually sufficient for simple and easily resolved samples such as less polar and 
medium polar non-ionic solutes, but for samples containing ionic and ionisable 
compounds, apart from changes in solvent strength, several other separation variables 
are to be altered to optimize band spacing, retention or peak shape. Some of the more 
commonly used variables are listed in Table 1.6. 
Table1.6: Variables for improving separation17 
Variable Comment 
  
Choice of organic solvent A  change  from  methanol  to  acetonitrile  or  THF  often 
 results in large changes in separation. 
  
Mobile phase pH A Change in pH may result in a major effect on band 
 spacing  for  samples  that  contain  ionic  or  ionisable 
 compounds. 
  
Solvent strength A  change  in  percent  organic  often  provides  significant 
 changes in retention and separation. 
  
Column type This refers to the choice of bonded-phases for reversed- 
 phase LC (C 18, C 8,Phenyl,cyano etc) 
  
Concentration   of   mobile The  most  common  additives  for  varying  band  spacing 
phase additives include amine modifiers, acid modifiers, buffers and salts. 
  
Temperature The temperature can be varied between 0 to 70ºC for the 
 purpose   of   controlling   band   spacing;   however, 
 temperatures of 25-60 ºC are more common. 
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For selectivity changes, it is sometimes desirable to substitute one organic 
solvent for another. The solvent strength monograph provides required information 
for such substitution of solvent in reversed-phase mobile phases.Stationary phase 
optimization is also an option for reversed-phase LC. Octadecyl and octyl are the 
most commonly used phases, but cyano and phenyl columns are also frequently used. 
Mobile phase optimization experiments should be performed for each column to be 
tested to obtain the desired separation. 
For the samples that contain acidic or basic compounds, retention may vary 
with both the ionic strength and pH of the buffer. If the pKa values are known for a 
group of compounds to be separated by RP-HPLC, and if these pKa values are 
different, then it is likely that a pH near (±2 units) the average pKa value of the 
mixture should provide good separation.The recommended additives for the reversed-
phase mobile phases in the case of samples that contain acids, bases or salts are given 
in Table 1.7. 
Table1.7: Recommended additives for reversed-phase mobile phases18. 
Sample characteristics Additives    
     
Basic compounds (ex: amines) 50mM Phosphate buffer, 30
 Mmtriethylamine (buffer pH 3.0)  
  
Acidic compounds (ex: carboxylic 
acids) 50mM  Phosphate  buffer,  1%  acetic  acid 
 (buffer pH 3.0)   
     
Mixture of acids and bases 50mM Phosphate buffer, 30
 mMtriethylamine, 1% acetic acid  
    
Cationic   salts   (ex:   
tetralkylquarternary 30   mMtriethylamine, 50mM sodium
ammonium compounds) nitrate    
  
Anionic salts 1% acetic acid, 50mM sodium  nitrate 
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A temperature of 40-600C appears to be convenient in reversed phase-LC, 
when sample component permits. Compared to ambient conditions operation at these 
temperatures usually doubles the column efficiency in terms of number of theoretical 
plates.Different concentrations of the various organic solvents are required to 
maintain constant solvent strength. Varying the pH of mobile phase may drastically 
alter separation selectively in RP-HPLC, if the sample components are acids or bases. 
When dealing with a sample component of weak base, pKa 8 the ion suppression 
technique can be used by adding an acidic buffer. If this is ineffective, an ion pair 
reagent, such as alkyl sulfonic acid may be added. For strong bases, pKa>8, ion pairs 
are more effective than ion suppression.Mobile phase composition has a major effect 
on band spacing; no other variable will generally prove as powerful for controlling 
values of separation. The separation goals in HPLC method development are 
summarized in Table 1.8. 
Any molecule has either n, π or σ or a combination of these electrons. These 
bonding (σ& π) and nonbonding (n) electrons absorb the characteristic radiation and 
undergoes transition from ground state to excited state. In general, non-bonding lone 
pair of electrons of hetero atoms is the least strongly bound in a molecule and in the 
bonding levels π – electrons have higher energy levels than the corresponding σ – 
electrons whilst in the anti-bonding levels the order is reversed.  
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Table 1.8:Separation goals in HPLC method development19. 
Goal Comment 
  
Resolution Precise and rugged quantitative analysis requires that Rs 
 be greater than 1.5. 
Separation time <5-10 min is desirable for routine procedures. 
  
Quantitation 2% for assays;  5% for less-demanding analyses 
 15% for trace analyses. 
  
Pressure <150 bar is desirable, <200 bar is usually essential (new 
 column assumed). 
  
Peak height Narrow peaks are desirable for large signal/noise ratios. 
  
Solvent Minimum mobile-phase use per run is desirable. 
Consumption  
 
Documentation of analytical figures of merit 
The originally determined analytical figures of merit Limit of Quantitation 
(LOQ), Limit of Detection (LOD), Linearity, time per analysis, cost, sample 
preparation etc., are documented. 
Evaluation of method development with actual samples 
The sample solution should lead to absolute identification of the analyte peak 
of interest apart from all other matrix components. 
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Determination of percent recovery of actual sample and demonstration of 
quantitative sample analysis 
• Percent recovery of spiked, authentic standard analyte into a sample 
matrix that is shown to contain no analyte is determined. Reproducibility 
of recovery (average ± standard deviation) from sample to sample and 
whether recovery has been optimized is determined. It is not necessary to 
obtain 100% recovery as long as the results are reproducible and known 
with a high degree of certainity. 
• The validity of analytical method can be verified only by laboratory 
studies. Therefore documentation of the successful completion of such 
studies is a basic requirement for determining whether a method is suitable 
for its intended applications. 
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Table .1.9: Steps involved in development of HPLC method20 
 
Literature survey: To avoid duplication of the method and invention of new 
method.Information about the solubility, the structure of the drugs and their Physico-
chemical properties for the known compounds and can be applied for the new 
compounds. 
 
 
 
Selection of chromatographic method: First reversed phase should be tried.If not 
successful, normal phase should be taken into consideration.For ion exchange or ion 
pair chromatography, first ion suppression by pH control and reversed phase 
chromatography should be tried. 
 
 
 
. Selection of stationary phase: Matching the polarity of sample and stationary phase 
and using a mobile phase of different polarity achieves a successful separation 
 
 
 
Selection of mobile phase: Reversed phase bonded packing, when used in 
conjunction with highly polar solvents. Mobile phase may be either single liquid or 
combination of liquids, which are compatible with sample, column and instrument. 
 
 
 
Selection of suitable detector: Detector is the eye of HPLC system and measures the 
compounds after their separation on the column. There are basically two types of 
detectors: bulk property detectors; Solute property detectors.UV detector is the first 
choice because of its convenience and applicability in case of most of the samples. 
The latest version of equipment is available with photo diode-array detectors. 
 
Chapter - 1                                                                                                  Introduction 
 
Dept. of Pharmaceutical Analysis           31         JKKMMRF College of Pharmacy 
 
 
 
1.6. ANALYTICAL METHOD VALIDATION21 
Method validation as per ICH can be defined as “Establishing documented 
evidence, which provides a high degree of assurance that a specific activity will 
consistently produce a desired result or product meeting its predetermined 
specifications and quality characteristics”. 
• Objective of validation 
There are two important reasons for validating assays in the pharmaceutical 
industry.The first, and by for most important is that assay validation is an integral part 
of the quality control system.The second is that current good manufacturing practice 
regulation requires assay validation. In industry it would be difficult to confirm that 
the product being manufactured is uniform and that meet the standards set to assure 
fitness for use. The varying nature of the differences between the analytical 
development laboratory and quality control laboratory is a good reason for validation 
program. 
Method validation study includes Specificity / Selectivity, Linearity, 
Accuracy, Precision, Limit of detection, Limit of Quantitation, Robustness, System 
suitability and Stability criteria. 
• Accuracy 
The accuracy of measurement is defined as the closeness of the measured value to 
the true value. In a method with high accuracy, a sample (whose “true value” is 
known) is analyzed and the measured value should ideally be identical to the true 
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value.Typically, accuracy is represented and determined by recovery studies but there 
are three ways to determine accuracy: 
Comparison to a reference standard 
Recovery of the analyte spiked into blank 
matrix or Standard addition of the analyte. 
The ICH documents recommended that accuracy should be assessed using a minimum 
of nine determinations over a minimum of three concentrations levels the specified 
range (i.e., three concentrations and three replicates of each concentration). Accuracy 
was tested (%Recovery and %RSD of individual measurements) by analyzing 
samples at least in triplicate, at each level (80%, 100% and 120% of label claim) is 
recommended. For each determination fresh samples were prepared and assay value is 
calculated. Acceptance criteria:T he accuracy should be within 98-102%. 
• Precision 
Precision can be defined as “the degree of agreement among individual test 
results when the procedure is applied repeatedly to multiple samplings of a 
homogeneous sample”. A more comprehensive definition proposed by the 
International Conference on Harmonization (ICH) divides precision into three types: 
 Repeatability 
 Intermediate 
 precision  
 Reproducibility 
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• Repeatability: Repeatability expresses the precision under the same operating 
conditions over a short interval of time. Repeatability is also termed intra-assay 
precision and involves multiple measurements of the same sample (different 
preparations) by the same analyst under the same conditions. At least 5 or 6 
determinations 
At two or three different concentrations should be done and the relative standard 
deviations were calculated. The % RSD can be calculated by, 
 
Where, RSD = relative standard deviation 
SD = standard deviation 
The standard deviation SD is given by, 
 
• Intermediate precision: It is the agreement of complete measurements 
(including standards) when the same method is applied many times within the 
same laboratory. Intermediate precision expresses within-laboratories 
variations: different days, different analysts, different equipment etc. 
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• Reproducibility:Reproducibility expresses the precision between laboratories 
and is often determined in collaborative studies or method transfer 
experiments. 
The precision of an analytical procedure is usually expressed as the variance, standard 
deviation or coefficient of variation of a series of measurements.  
Acceptance criteria:The% RSD should be less than 2. 
• Linearity 
The linearity of an analytical procedure is its ability (within a given range) to 
obtain test results, which are directly proportional to the concentration (amount) of 
analyte in the sample. 
It is a measure of how well a calibration plot of response vs. concentration 
approximates a straight line. Linearity can be assessed by performing single 
measurements at several analyte concentrations. The data are then processed using a 
linear least squares regression. The Resulting plot slope, intercept and correlation 
coefficient provide the desired information on linearity. 
Acceptance criteria:Correlation coefficient(R2)>0.998 
• Specificity 
Specificity is the ability to assess unequivocally the analyte in the presence of 
components which may be expected to be present; these include impurities, 
degradants and matrix etc. Lack of specificity of an individual analytical procedure 
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may be compensated by other supporting analytical procedures. This definition has 
the following implications: 
Identification: To ensure the identity of an analyte. 
Purity Tests: To ensure that all the analytical procedures performed allow an accurate 
statement of the content of impurities of an analyte, i.e. related substances test, heavy 
metals, residual solvents content etc. 
Assay (content or potency): To provide an exact result which allows an accurate 
statement on the content or potency of the analyte in a sample. 
Acceptance criteria:No interference should be present. 
• Limit of Detection 
The detection limit of an individual analytical procedure is the lowest amount 
of analyte in a sample which can be detected but not necessarily quantitated as an 
exact value. LOD can be defined as the smallest level of analyte that gives a 
measurable response. The detection limit is usually expressed as the concentration of 
the analyte (percentage parts per million) in the sample. It is usually determined by 3 
ways: 
 Based on Visual Evaluation 
 Based on Signal-to-Noise 
 Based on the Standard Deviation of the Response 
and the slope  
 The limit of detection may be expressed as 
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Where, σ = the standard deviation of the 
response S = the slope of the calibration 
curve. 
Acceptance criteria:S/N should be 3:1 
• Limit of Quantitation 
The quantitation limit of an analytical procedure is the lowest amount of analyte 
in a sample which can be quantitatively determined with suitable precision and 
accuracy. LOQ is usually expressed as the concentration of the analyte (percentage 
parts per million) in the sample. . It is usually determined by 3 ways: 
 Based on Visual  
 Evaluation Based on Signal-to-Noise  
 Based on the Standard Deviation of the Response and the slope 
The limit of Quantitation may be expressed as:  
 
Where, σ = the standard deviation of the response 
S = the slope of the calibration curve. 
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Acceptance criteria:S/N should be 10:1 
• Robustness 
It is defined as a measure of its capacity to remain unaffected by small but 
deliberate variations in method parameters and provides an indication of its reliability 
during normal usage.It involves a number of method parameters that are varied within 
a realistic range and the quantitative influence of the variables is determined. The 
typical variations are: 
 Influence of variations of pH in a mobile phase. 
 Influence of variations in mobile phase composition. 
 Different columns (different lots and/or suppliers). 
 Temperature. 
 Flow rate. 
• System Suitability Testing 
Prior to the analysis of samples each day, the operator must establish that the 
HPLC system and procedure are capable of providing data of acceptable quality. This 
is accomplished with system suitability experiments, which can be defined as tests to 
ensure that the method can generate results of acceptable accuracy and precision. 
The parameters that can be used to determine system suitability prior to 
analysis, includes Plate number (N), Tailing factor, k and/or α, Resolution (Rs)and 
Relative standard deviation (RSD) of peak height or peak area for repetitive 
injections. Typically at least two of these criteria are required to demonstrate system 
suitability for any method. 
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Table 1.10: Acceptance criteria of validation for HPLC22 
 
• Stability Indicating Method 
Stability-indicating methods according to 1987 guideline were defined as the 
‘quantitative analytical methods that are based on the characteristic structural, 
chemical or biological properties of each active ingredient of a drug product and that 
will distinguish each active ingredient from its degradation products so that the 
active ingredient content can be accurately measured.’ 
This definition in the draft guideline of 1998 reads as: ‘Validated quantitative 
analytical methods that can detect the changes with time in the chemical, physical, 
or microbiological properties of the drug substance and drug product, and that are 
specific so that the contents of active ingredient, degradation products, and other 
components of interest can be accurately measured without interference.’ 
The stability-indicating assay is a method that is employed for the analysis of 
stability samples in pharmaceutical industry. With the advent of International 
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Conference on Harmonisation (ICH) guidelines, the requirement of establishment of 
stability-indicating assay method (SIAM) has become more clearly mandated. The 
guidelines explicitly require conduct of forced decomposition studies under a variety 
of conditions, like pH, light,oxidation, dry heat, etc. and separation of drug from 
degradation products. The method is expected to allow analysis of individual 
degradation products. 
• Forced degradation studies 
Forced Degradation is theStudy designed to intentionally degrade a drug 
substance or drugproduct under different stress conditions like acid, base, oxidation, 
Heat, light, moisture. 
Forced degradation studies are indispensable in the development of stability-
indicating and degradant-monitoring methods as part of a validation protocol. Forced 
degradation studies also provide invaluable insight in investigating degradation 
products and pathways of drug substances and products. Even though the ICH and 
FDA guidance documents only call for the inclusion of these studies in Phase III of 
the regulatory submission process, it is strongly recommended these studies be started 
as early as possible to be able to provide valuable information that can be used to 
assess the inherent stability of a drug, and to improve formulations and the 
manufacturing process. 
Given that no specific set of conditions will be applicable to all drug 
substances and products, the pharmaceutical scientist should ensure the stress 
conditions are consistent with product decomposition under normal manufacturing, 
storage, and intended use conditions. Recommended stress factors include high and 
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low pH, elevated temperature, photolysis, and oxidation. Care should be taken to 
avoid under stressing or unduly over-stressing the drug substance or product, for this 
may lead to aberrant and non-representative results. A degradation level of 
approximately 10% of the drug substance should be optimal for method optimization. 
• Forced Degradation Studies are performed 
 To understand the reactive chemistry of the drug substance 
 Help anticipate future stability issues of both drug substance and 
drug product Provides useful information for formulation and 
stability 
 Generate a sample for development of stability indicating methods for 
formal stability study support 
Table 1.11: Example Conditions for Forced Degradation23 
Study Condition 
Acidic 0.1N HCl 
Basic 0.1N NaOH 
Oxidation 3% H2O2 
Neutral pH - 7 Phosphate Buffer 
Photolysis (UV) 1000 Watt h/M2 
Photolysis (Fluorescence) 6x106 lux h 
Goal: Degrade API up to 5-10%. 
Stability Indicating Method (SIM): A validated method that can accurately and 
precisely quantitative the decrease of the API content due to degradation. 
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• Is specific for the drug substance 
• Shows a decrease in assay value (correlated to drug substance loss) due to 
degradation  
• Has no interference from excipients, impurities or degradation products 
• Detects and quantities impurities and degradation products 
FDA Comments on Peak Purity24 
The purity testing provided was based on one wavelength and on one lot. This 
is not adequate to assess peak purity. Typically, the entire UV-Vis spectra (with 
consideration for solvent and noise controls) is analyzed at various points in the peak 
area (especially at leading and trailing edge) and at varying concentrations to indicate 
purity. There is chromatographic software to perform this type of analysis. 
In addition, other instruments and techniques are used to assess peak purity. 
We are unable to fully evaluate the purity of the compound based solely on the 
information provided. 
Role of Photodiode Array Detector in LC Method Development/Validation25 
• Spectral Contrast Software For Peak Tracking and Identification  
• Potential For Peak Purity System Suitability Criteria 
• Peak Purity or Homogeneity Information Indicative of Co-Elution 
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What is needed for PDA Peak Purity Calculations? 
• Compounds must have UV Absorbance 
• Some Degree of Chromatographic Resolution 
• Some Degree of Spectral Differences Between Compounds. 
Stability indicting method is needed 
• To support long term stability testing 
• Demonstrate how the quality of the drug substance or product changes over 
time in response to environmental factors like 
• Temperature  
• Humidity  
• Light 
• Establishes storage and packaging conditions. 
General points to consider 
Some basic points to note in the test method are: 
• The sample and standard should be dissolved in the mobile phase. If 
that is not possible, then avoid using too high a level of the organic 
solvent as compared to the level in the mobile phase. 
• The sample and standard concentrations should be close if not the 
same. 
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• The samples should be bracketed by standards during the analytical 
procedure. 
• Filtration of the samples before injection is occasionally observed 
Filtration Will remove particulates (centrifugation performs the same 
function) that may clog columns. 
• Adhesion of the analyte to the filter can also happen. This will be of 
importance especially for low-level impurities. Data to validate this 
aspect should be submitted by the applicant. 
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2. LITERATURE REVIEW 
Bhargav.Y.et al26,(2013)A  new, simple, accurate, rapid,  precise RP-HPLC 
method was  developed for  the  simultaneous estimation of ofloxacin and tinidazole 
in bulk and pharmaceutical dosage form. A good chromatographic separation was 
achieved with Intersil ODS C18 250×4.6mm.5µ) column and ammonium acetate 
buffer pH 4.0, acetonitrile, and tetrahydrofuran 60:30:10 was used as mobile phase at 
a flow rate of 1.0ml/min and the detection was carried out at a wavelength of 304 nm. 
The retention times was found to be 2.350 min for ofloxacin and 3.613 min for 
tinidazole. The linearity of the method was in the concentration range of 15-
35µg/mL for ofloxacin and 45-105µg/mL for tinidazole. The developed method was 
validated for system suitability, specificity, precision, recovery and linearity 
according to ICH guidelines. The method was successfully applied for routine 
analysis for the determination of oflaxacin and tinidazole in bulk and dosage forms. 
Pankaj.B et al27,(2012) A simplereverse phase liquid chromatographic 
method has been developed and subsequently validated for simultaneous 
determination of Ofloxacin and Ornidazole in infusion dosage form. The separation 
was carried out using a mobile phase containing methanol and buffer (equal 
proportion of 0.01M orthophosphoric acid and 0.01M sodium phosphate monobasic 
dihydrate) with pH 4.00 adjusted by 20% of triethylamine in the ratio of 60:40 v/v. 
The column used was HiQSil C18 (150 mm x 4.6mm i.d, 5 µ) with flow rate of 1 mL 
/ min using UV detection at 300 2 nm. The described method was linear over a 
concentration range of 1.25-10 µg/mL (r >0.9991) forOfloxacin and 3.12-25 µg/mL 
(r >0.9992) for Ornidazole. Separation was achieved within 5 min.  
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The mean % recovery was found to be 99.94% for Ofloxacin and 100.27 % 
for Ornidazole. The limit of detection (LOD) for Ofloxacin and Ornidazole were 
found to be 0.146 and 0.25 µg/mL respectively. Whereas, the limit of quantification 
(LOQ) for Ofloxacin and Ornidazole was 0.44 and 0.77 µg/mL respectively. 
Vasudevan.Metal et al28, (2009) A simple Reverse   phase   liquid 
chromatographic method has been developed and subsequently validated for 
simultaneous determination of Ofloxacin and Tinidazole in combination. The 
separation was carried out using a mobile phase consisting of 0.5%v/v Triethylamine 
buffer of pH 3.0 and Acetonitrile in the ratio of 73: 27. The column used was 
KromasilC , 5µ, 15 cm × 4.6 mm id with flow rate of 1.2 ml / min using PDA 
detection at 303 nm. The described method was linear over a concentration range of 
10-50 µg/ml and 30-150 µg/ml for the assay of Ofloxacin and Tinidazole 
respectively. Ambroxol (50 µg/ml) was used as internal standard. The retention times 
of Ofloxacin, Tinidazole and Ambroxol were found to be 2.3, 4.1 and 5.1min 
respectively. Results of analysis were validated statistically and by recovery studies. 
The limit of quantification (LOQ) for Ofloxacin and Tinidazole were found to be 10 
and 30 µg/ml respectively. The results of the study showed that the proposed RP-
HPLC method is simple, rapid, precise and accurate, which is useful for the routine 
determination of Ofloxacin and Tinidazole bulk drug and in its pharmaceutical 
dosage form. 
Rama Kotaiah.M et al29 ,(2010) A simple reverse phase liquid 
chromatographic method has been developed and subsequently validated for 
simultaneous determination of formoterol fumarate and budesonide in combination. 
The separation was carried out using a mobile phase consisting of 2mM phosphate 
buffer and Acetonitrile with pH 3.0 adjusted with phosphoric acid in the ratio of 
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5%v/v. The column used was Phenomenex C18, (250 mm x 4.6 mm i.d, 5m) with          
flow rate of 1 ml / min using PDA detection at 303 nm. The described method was 
linear over a concentration range of 5-50 g/ml and 15-150 g/ml for the assay of 
Ofloxacin and Tinidazole respectively. Ambroxol (50 g/ml) was used as internal 
standard. The retention times of Ofloxacin, Tinidazole and Ambroxol were found to 
be 2.3, 4.1 and 5.1min respectively. Results of analysis were validated statistically 
and by recovery studies. The limit of quantification (LOQ) for Ofloxacin and 
Tinidazole were found to be 10 and 30 µg/ml respectively. The results of the study 
showed that the proposed RP-HPLC method is simple, rapid, precise and accurate, 
which is useful for the routine determination of Ofloxacin and Tinidazole bulk drug 
and in its pharmaceutical dosage form. 
Gandhimathi Met al30,(2006) were developed A simple, accurate and precise 
high performance thin layer chromatographic for the estimation offormoterolfumarate 
and budesonide simultaneously in tablet dosage form. The method employed silica 
gel 60GF254 precoated plates as stationary phase and a mixture of n-butanol: ethanol: 
ammonia (5:5:4 %v/v/v) as mobile phase. The plate was scanned and quantified at 
295 nm using Camag TLC scanner. The method was validated for linearity, accuracy, 
precision, repeatability and specificity, proving its utility in estimation of ofloxacin 
and ornidazole in combined dosage form. 
Nageswara Rao M  et al31,(2015)were developed A   simple,   precise and   
accurate   isocratic   high-performance   liquid   chromatography method   is   
developed   for   the simultaneous estimation of Cefixime and Ornidazole in bulk 
drug and pharmaceutical dosage form. The separation and quantification is carried 
out using YMC Pack Pro C18, 250X4.6, 5 um analytical columns. The mobile phase 
comprises of 0.1M NaHPO: Methanol (500: 500 v/v). The flow rate is 1.2 mL/min 
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The eluent is monitored at 270 nm. nm. The retention time of cefixime and ornidazole 
are 3.25min and 4.450 min, respectively. The method  is, validated in terms of 
linerarity, sensitivity , precision. Accuracy, specificity, selectivity and robustness. 
The  stress testing is carried out under acidic, alkaline, oxidation, thermal degradtin 
and photolytic conditions. The degradation products are well resolved from the 
cefixime and ornidazole peaks. 
 
Srinivasa Rao K et al32,(2014)were developed estimation of Ofloxacin 
(OFL) and Tinidazole (TNZ) in in bulk and pharmaceutical dosage form, without 
prior separation, by three different techniques (Simultaneous equation, absorbance 
ratio method and First order derivative method). Materials and Methods: The present 
work was carried out on Shimadzu electron UV1800 double beam UV-Visible 
spectrophotometer.The absorption spectra of reference and test solutions were carried 
out in 1 cm matched quartz cell over the range of 200 - 400 nm. The first method is 
the application of simultaneous equation. Where the linearity ranges for OFL and 
TNZ were 5-30 µg/ml and 10-50 µg/ml respectively. The second method is the 
determination of ratio of absorbance at 278nm, the maximum absorption of TNZ and 
isobesticwavelength 283 nm, the linearity ranges for OFL and TNZ were 5-30 µg/ml 
and 10-50µg/ml respectively. 
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3. OBJECTIVES AND AIM OF THE WORK 
3.1. AIM & OBJECTIVE OF THE WORK 
There is several basic criteria for new method development of drug molecules. 
For example a) The drug or drug combination may not be official in any 
pharmacopoeias b) A proper analytical procedure for the drug may not be available in 
the literature due to patent regulations. c) The existing analytical procedures may 
require expensive reagents and solvents. It may also involve cumbersome extraction 
and separation procedures and these may not be reliable. 
It is important for an analyst to develop stable, accurate and validated method 
for estimation of marketed formulations and specially the widely used formulations. A 
new combination of Formoterol Fumarate and Budesonide has been selected. 
After extensive literature review, The Literature survey reveals that, HPLC 
and Stability Indicating methods were reported for simultaneous estimation of 
Formoterol Fumarate with other combinations and HPLC methods are reported for 
individual drugs but Stability indicating of Formoterol Fumarate and Budesonide 
combination not reported in any literature. 
The present work describes development of simple, precise and accurate, 
validated stability indicating RP-HPLC method for the simultaneous estimation of 
formoterol fumerate and budesonide in its pure and pharmaceutical inhalation powder 
form as per ICH – guidelines. 
It becomes necessary, therefore to develop newer analytical method and 
Stability indicating studies for this drug. 
Chapter - 3                                                                  Objectives and Aim of the Work 
 
Dept. of Pharmaceutical Analysis           49         JKKMMRF College of Pharmacy 
 
 
 
Reported optimized methods are not significantly stable, as per ICH guidelines 
for stability study maximum cases drugs are degraded, so there is a less justification 
to indicate the method” stability indicating”. 
Keeping the above facts in mind the present work was planned to develop 
such an method which should be sufficiently stable by developed such a mobile phase 
for analysis, accurate, rapid and validated, by bring down to retention time for both 
the drug and all validated parameters within limit 
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3.2. PLAN OF WORK 
The number of drugs introduced into the market is increasing every year. 
Very often there is a time lag from the date of introduction of a drug into the market 
to the date of its inclusion in pharmacopoeias. This happens because of the possible 
uncertainties in the continuous and wider usage of these drugs, reports of new 
toxicities, development of patient resistance and introduction of better drugs by 
competitors. 
Under these conditions, standards and analytical procedures for these drugs 
may not be available in the pharmacopoeias. It becomes necessary, therefore to 
develop newer analytical methods for such drugs. 
The total work was planned and constructed s follows to achieve the objective of 
the work Solubility testing of the drugs using different organic solvents. 
 Determination of wavelength by using UV- Visible spectrophotometer. 
 Checking of linearity by using different concentrations of the drug under study 
by UV-Visible spectrophotometer method. 
 Calibration of HPLC using standard procedures. 
 Selection of proper mobile phase the optimization in HPLC using 
several trials. Setting of proper optimized method as per ICH Q2B 
guidelines. 
 Application of optimized validation method for the analysis of 
method formulation. 
 Perform the stability study as per ICH guidelines. 
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4. DRUG PROFILE  
4.1. FORMOTEROL FUMARATE 
 
 
 
 
 
Fig. 3.1Structure of  Formoterol  Fumarate 
 
Nomenclature:N-[2-hydroxy-5-(1-hydroxy-2-{[1-(4-
methoxyphenyl)propan-2-yl]amino}ethyl)phenyl]formamide 
 
Molecular formula : C19H24N2O4 
 
Molecular weight : 344.4049 
 
Solubility: Freely soluble in glacial acetic acid, soluble in methanol, sparingly 
soluble in ethanol and isopropanol, slightly soluble in water and practically 
insoluble in acetone, ethyl acetate, and diethyl ether. 
 
Description : Formoterol fumarate is a white to yellowish crystalline powder. 
 
Category: Sympathomimetics, Adrenergic beta-2 Receptor Agonist, 
Bronchodilators Agents. 
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4.2. BUDESONIDE 
 
 
 
 
 
IUPAC Name: (1S,2S,4R,8S,9S,11S,12S,13R)
9,13-dimethyl-6-propyl
14,17-dien-16-one 
 
Molecular formula: C25H34O6
 
Molecular weight: 430.5339
 
Solubility: Freely Soluble in Chlorofor
Sparingly Soluble in ethanol,
 
Category: Corticosteroids.
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Fig. 3.2: Structure of Budesonide 
 
-11-hydroxy-8-
-5,7dioxapentacyclo[10.8.0.0^{2,9}.0^{4,8}.0^{13,18}]icosa
 
 
m, insoluble in water, heptane, 
 
 
Drug Profile 
 
(2-hydroxyacetyl)-
-
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5. MATERIALS AND METHODS 
5.1. CHEMICALS AND STANDARDS USED 
 
 
Table 5.1: List of chemicals and standards used 
 
 
S.No Chemicals Manufacturer Name Grade 
1. Water Merck HPLC grade 
    
2. Methanol Merck HPLC grade 
3. Acetonitrile Merck HPLC grade 
4. Ortho phosphoric acid Merck G.R 
5. KH2PO4 Merck G.R 
6. K2HPO4 Merck G.R 
7. 0. 22µ membrane filter Advanced lab HPLC grade 
8. 0.45µ filter paper Millipore HPLC grade 
9. 
FormoterolFumarate 
and Budesonide 
Torrent 
pharmaceuticals  
10. 
FormoterolFumarate 
and Budesonide 
(Budamate 400) 
Obtained from local 
pharmacy, Hyderabad Capsule form 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter - 5                                                                                Materials and Methods 
 
Dept. of Pharmaceutical Analysis           54         JKKMMRF College of Pharmacy 
 
 
 
Instruments used 
 
Table 5.2 List of instruments used 
 
S.No Instrument name Model number Soft ware 
Manufacturers 
Name     
     
 HPLC-auto Separation  module Empower-  
1 sampler –PDA 2690, PDA detector software Waters 
 detector 996 version-2  
     
2 
U.V double beam 
UV 3000+ 
U.V win soft 
Lab India 
spectrometer ware    
     
 Digital weighing    
3 balance(sensitivity ER 200A - Ascoset 
 5mg)    
     
4 pH meter PHAN - Lab India 
     
5 Sonicator SE60US - Enertech 
     
 
 
 
5.2. METHODS 
Preparation of various buffers used in trials: 
Preparation of Potassium dihydrogen orthophosphate buffer (pH-4.5) 
About1.17 g of Potassiumdihydrogen orthophosphate was accurately 
weighed and taken into 250 ml volumetric flask. 
Then add 150 ml of HPLC water,dissolve completely to get a clear 
solution. Make up the volume up to the mark. 
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The pH was adjusted to 4.5 with Orthophosphoric acid and filtered through  
0.45 µm membrane filter  Sonicate for 15 min. 
Preparation of mobile phase: 
A Combination of Potassium dihydrogen orthophosphate buffer (pH-4.5)(refer 
7.2.1.1)and Acetonitrile was mixed in the ratio of 30:70, The pH was adjusted to 4.5 
with Orthophosphoric acid and filtered through 0.45 µm membrane filter. 
This prepared solution was used as mobile phase. This solution was also used 
for specificity blank solution. 
Preparation of standard solution of Formoterol Fumarate and Budesonide for 
trials: 
Standard solution of  Formoterol Fumarate and Budesonide were prepared by 
dissolving 10 mg of each drug in 10 mL of mobile phase. Further dilution was made 
by adding 1 mL of the stock solution to 10 mL standard flask and making up the 
volume with the mobile phase. 
Preparation of Solutions for assay 
Preparation of the Formoterol Fumarate and Budesonide standard and sample 
solution 
Sample solution preparation 
22 mg of Formoterol Fumarate and Budesonide capsule powder were 
accurately weighed and transferred into a 10 ml clean dry volumetric flask, 2 ml of 
diluent was added and sonicate to dissolve it completely and making volume up to the 
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mark with the same solvent(Stock solution). Further pipette out 0.2 ml of the above 
stock solution into a 10ml volumetric flask and was diluted up to the mark with 
diluent. 
Standard solution preparation 
10 mg Formoterol Fumarate and 15 mg of Budesonide working standard was 
accurately weighed and transferred into a 10ml clean dry volumetric flasks separately 
and add about 2 ml of diluent to both flasks and sonicate to dissolve it completely and 
make volume up to the mark with the same solvent (Stock solution).Further pipette 
out 0.3ml and 0.45ml of the above stock solutions into a 10ml volumetric flask and 
was diluted up to the mark with diluent. 
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6. RESULTS AND DISCUSSION 
6.1. SOLUBILITY STUDIES  
 
These studies are carried out at 25°C 
 
Table 6.1: Solubility studies 
 
Solvent Name FormoterolFumarate Budesonide 
   
Water Soluble Insoluble 
   
Methanol Freely  Soluble Freely Soluble 
   
Acetonitrile Soluble Soluble 
   
 
 
6.2. DETERMINATION OF WORKING WAVELENGTH (λmax) 
 
In simultaneous estimation of two drugs isobestic wavelength is used. Isobestic point 
is the wavelength where the molar absorptivity is the same for two substances that are 
interconvertible. So this wavelength is used in simultaneous estimation to estimate 
both drugs accurately. 
 
6.2.1. Preparation of standard solution of Formoterol Fumarate 
 
About 50mg of Formoterol Fumarate was weighed and transferred in to 50ml 
volumetric flask and dissolved in 25mL of methanol and then make up to the mark 
with the mobile phase and 10µg /mL of solution was prepared by diluting 0.1mL to 
10mL with mobile phase 
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6.2.2. Preparation of standard solution of Budesonide 
 
About 50mg of Budesonide was weighed and transferred into 50ml volumetric flask 
and dissolved in 25mL of mobile phase and then diluted up to the mark with mobile 
phase and 10µg /mL of solution was prepared by diluting 0.1mL to 10mL with mobile 
phase. 
 
Fig.6.1: Selection of wavelength 
 
6.2.3. Results 
 
The wavelength at 228 nm has been selected, as the isobestic point. 
 
6.3. METHOD DEVELOPMENT 
 
Aliquots of the mixed solutions containing FormoterolFumarateand Budesonide were 
prepared and a number of eluting experiments were conducted for the optimization of 
separation of drugs using mobile phase. 
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Trial - 1 
 
For Formoterol Fumarate 
 
Mobile Phase: Water and Methanol were mixed in the ratio of 30:70 and sonicated to 
degas.20 µL of  prepared solution was injected into the HPLC and the 
chromatograms were recorded 
 
Chromatographic conditions 
Name of the column : waterssymmetryC18 (4.6*150mm) 5µm 
Mobile phase : Water : Methanol ( 30:70 ) 
Elution mode : Isocratic. 
Flow rate : 1 mL/min. 
Detection wavelength : 228 nm. 
Injection volume : 20.00 µL. 
Run time : 10.00 min. 
Retention Time : 3.662 min. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6.2:Chromatogram of Trial – 1 
 
Chapter - 6                                                                                 Results and Discussion 
 
Dept. of Pharmaceutical Analysis           60         JKKMMRF College of Pharmacy 
 
 
 
Table 6.2: Results of Trial -1 
 
Drugs RT Peak Area TP  TF Rs 
       
FF 3.662 83319 
 
2975 1.35 - 
       
 
Observation & Conclusion: 
 
Formoterol Fumarate is eluted at 3.662 min and the results of the 
chromatogram along with peak area as shown as below and the results of the 
chromatogram are given in Table 6.2. From the chromatogram it was 
observed that the retention time, theoretical plates and tailing factor for FF 
was good. So no more trials were required for obtaining proper retention time, 
go for next trail for Budesonide.  
 
Trial– 2:- For Budesonide 
Mobile Phase : 
 
Water and Methanol were mixed in the ratio of 20:80 andsonicated to 
degas.20 µLof prepared solution was injected into the HPLC and the 
chromatograms were recorded 
 
Chromatographic conditions 
 
Name of the column : waterssymmetryC18 (4.6 χ 150mm) 5µm 
Mobile phase : Water : Methanol (20:80) 
Elution mode : Isocratic. 
Flow rate : 1 mL/min. 
Detection wavelength : 228 nm. 
Injection volume : 20.00 µL. 
Run time : 10.00 min. 
Retention Time : 1.514 min. 
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Fig. 6.3: Chromatogram of Trial – 2 
 
 
\Table 6.2: Results of Trial -2 
 
         
 Drugs RT Peak Area  TP TF Rs 
        
 
BU 1.514 388193 
 
1162 1.19 - 
        
 
 
Observation& Conclusion: 
 
Budesonide is eluted at 1.514 min and the chromatogram along with peak area as 
shown as above. Theoretical plates, tailing factor and the results of the chromatogram 
are given table 6.2 .From the chromatogram it is observed that theoretical plates were 
not good, so go for next trial. 
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Trial – 3 
 
Mobile Phase: 
 
 Water and Methanol were mixed in the ratio of 30:70 and sonicated to 
degas.20 µL of prepared solution was injected into the HPLC and the chromatograms 
were recorded 
 
Chromatographic conditions 
 
Name of the column : Waters symmetry C18 (150x4.6 ID) 3.5 µm 
Mobile phase : Water : Methanol ( 30:70 ) 
Elution mode : Isocratic. 
Flow rate : 1 mL/min. 
Detection wavelength : 268 nm 
Injection volume : 20.00 µL. 
Run time : 8.00 min. 
Retention Time : 2.422 min. 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6.4: Chromatogram of Trial –3. 
 
 
 
Chapter - 6                                                                                 Results and Discussion 
 
Dept. of Pharmaceutical Analysis           63         JKKMMRF College of Pharmacy 
 
 
 
Table 6.4: Results of Trial -2 
 
Drugs RT Peak Area TP  TF Rs 
       
BU 2.422 713281 
 
1720 1.17 - 
       
 
Observation & Conclusion: 
 
Budesonide is eluted at 2.422 min and the chromatogram along with peak area as 
shown. . From the chromatogram it is observed retention time was good. So go for 
combination. 
 
Trial -4 :- Combination of both drugs 
 
Mobile Phase: 
 
Potassium dihydrogen phosphate buffer (pH-4.5), Methanol were mixed in the ratio 
of 20 : 80.It was filtered through 0.45 µm membrane filter and degassed, 20 µLof 
prepared solution was injected into the HPLC and the chromatograms were recorded. 
 
Chromatographic conditions 
 
Name of the column : Waters symmetry C18 (150x4.6 ID) 3.5 µm 
Mobile phase : Potassium dihydrogen phosphate buffer 
pH - 4.5) :Methanol (20:80)  
Elution mode : Isocratic. 
Flow rate : 1 mL/min. 
Detection wavelength : 228 nm. 
Injection volume : 20.00 µL. 
Run time : 10.00 min. 
Retention Time : FF - 1.593 min & BU - 3.526 min. 
 
Chapter - 6                                                                                 Results and Discussion 
 
Dept. of Pharmaceutical Analysis           64         JKKMMRF College of Pharmacy 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6.5:Chromatogram of Trial – 4 
 
 
Table 6.5:Results of Trial -4 
 
Drug RT Peak Area TP TF Rs 
      
FF 1.593 27221 2760 2.05 - 
      
BU 3.526 126318 2813 1.16 7.7 
      
 
 
Observation & Conclusion: 
 
From the figure 8.4it was observed that FF is eluted at 1.593 min and BU is 
eluted at 3.526 min. The results of the chromatogram along with peak area, theoretical 
plates, tailing factor and resolution were given above. From the chromatogram it was 
observed that the sample solution injected consisted of two drugs and separation was 
not good and tailing factor for FF is not within limits. Therefore this trial was not 
considered. 
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Trial – 5 
 
Mobile Phase: 
 
Potassium dihydrogen phosphate buffer (pH-4.5),Methanol were mixed in the ratio of 
30 : 70.It was filtered through 0.45 µm membrane filter and degassed20 µLof 
prepared solution was injected into the HPLC and the chromatograms were recorded. 
 
Chromatographic conditions 
 
Name of the column : Waters symmetry C18 (150x4.6 ID) 3.5 µm 
Mobile phase : Potassium dihydrogen phosphate buffer 
pH - 4.5) :Methanol (30:70)  
Elution mode : Isocratic. 
Flow rate : 1 mL/min. 
Detection wavelength : 228 nm. 
Injection volume : 20.00 µL. 
Run time : 10.00 min. 
Retention Time : FF - 1.985 min. BU - 2.709 min. 
 
 
 
 
Fig. 6.6:Chromatogram of Trial -5 
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Table 6.6:Results of Trial -5 
 
Drug RT Peak Area TP TF Rs 
      
FF 1.985 117004 1728 1.38 - 
      
BU 2.709 382091 2779 1.29 3.6 
      
 
 
Observation& Conclusion: 
 
From the figure 6.6 it is observed that FF is eluted at 1.985 min and BU is eluted at 
2.709 min. The   results of the chromatogram along with peak area, theoretical plates, 
tailing factor and resolution are given. From the chromatogram  it was observed that 
the sample solution injected consisted of two drugs and separation was not good and 
retention time and theoretical plates for FF is not good. Therefore this trial was not 
considered 
 
Trial - 6 
 
Mobile Phase: 
 
Potassium dihydrogen phosphate buffer (pH-4.5), Acetonitrile were mixed in the ratio 
of 20: 80.It was filtered through 0.45 µm membrane filter and degassed20 µL of 
prepared solution was injected into the HPLC and the chromatograms were recorded. 
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Chromatographic conditions 
 
 
Name of the column : Waters symmetry C18 (150x4.6 ID) 3.5 µm 
Mobile phase : Potassium dihydrogen phosphate buffer 
pH - 4.5) :Acetonitrile (20:80) 
Elution mode : Isocratic. 
Flow rate : 1 mL/min. 
Detection wavelength : 228 nm. 
Injection volume : 20.00 µL. 
Run time : 10.00 min. 
Retention Time : FF - 1.782 min.BU - 4.006 min. 
 
 
 
Fig. 6.7:Chromatogram of Trial -6 
 
 
Table 6.7:Results of Trial -6 
 
Drug RT Peak Area TP TF Rs 
FF 1.782 24154 3164 1.61 - 
BU 4.006 13125 2892 1.21 8.4 
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Observation & Conclusion: 
 
Though the resolution and tailing factor were good for FF and BU, the retention time 
was not satisfactory for FF and further trials has been done in order to achieve good  
retention time. 
Trial –7 
 
Mobile phase 
 
Potassium dihydrogen phosphate buffer (pH-4.5), Acetonitrile were mixed in the 
ratio of 25 : 75.It was filtered through 0.45 µm membrane filter and degassed20 µL 
of  prepared solution was injected into the HPLC and the chromatograms were 
recorded. 
 
Chromatographic conditions 
 
Name of the column : Waters symmetry C18 (150x4.6 ID) 3.5 µm 
Mobile phase : Potassium dihydrogen phosphate buffer 
pH - 4.5) :Acetonitrile (25:75) 
Elution mode : Isocratic. 
Flow rate : 1 mL/min. 
Detection wavelength : 228 nm. 
Injection volume : 20.00 µL. 
Run time : 10.00 min. 
Retention Time : FF - 2.034 min. BU - 3.511 min. 
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Fig. 6.8 Chromatogram of Trial -7 
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Table 6.8: Results of Trial -6 
 
Drug RT Peak Area TP TF Rs 
      
FF 2.034 133805 1708 1.19 - 
      
BU 3.511 423920 3721 1.21 6.7 
      
 
Observation & Conclusion: 
 
The FF peak was observed at 2.034min, BU peak was observed at 3.511 min with 
tailing factors 1.19 and 1.21 respectively. Lack of enough theoretical plates was 
observed for FF. Hence this trial was not considered. So go for next trails. 
 
Trial-8 
 
Mobile phase 
 
Potassium dihydrogen phosphate buffer (pH-4.5), Acetonitrile were mixed in the ratio 
of 30: 70.It was filtered through 0.45 µm membrane filter and degassed20 µLof 
prepared solution was injected into the HPLC and the chromatograms were recorded. 
 
Chromatographic conditions 
Name of the column : Waters symmetry C18 (150x4.6 ID) 3.5 µm 
Mobile phase : Potassium dihydrogen phosphate buffer 
pH - 4.5) :Acetonitrile (30:70) 
Elution mode : Isocratic. 
Flow rate : 1 mL/min. 
Detection wavelength : 228 nm. 
Injection volume : 20.00 µL. 
Run time : 10.00 min. 
Retention Time : FF - 2.051 min.& BU - 4.234 min 
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Fig. 6.9: Chromatogram of Trial -8 
 
Table6.9:Results of Trial -8 
Drug RT Peak Area TP TF Rs 
      
FF 2.051 140672 2419 1.17 - 
      
BU 4.234 427794 3591 1.21 8.6 
      
 
 
Observation& Conclusion: 
 
The retention time was good for both FF and BU, the tailing factor was less than 2 
and the number of theoretical plates were more than 2000 for both and the resolution 
was good, the details are given So this trail has been chosen as optimised method and 
further work was continued with this developed method for the validation. 
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6.4.Optimised chromatographic conditions 
 
Table 6.10: showing chromatographic conditions of the optimized parameters 
Parameters Conditions  
   
Stationary phase (column) 
Waters symmetry C18 (150x4.6 ID) 3.5 
µm)  
   
 Potassium dihydrogen phosphate buffer pH - 
Mobile phase 4.5) :Acetonitrile (30:70)  
   
Flow rate (mL/min) 1.0 mL/min  
   
Run time (minutes) 10 min  
   
Column temperature (°C) Room temperature(20-25
oC ) 
 
   
Volume of injection loop (µL) 20µL  
   
Detection wavelength (nm) 228 nm  
   
 
Table 6.11: Results of FF and BU (Sample) for assay 
ASSAY 
Name 
Retention time 
(min) Peak Area TF Efficiency Resolution 
      
FF 2.093 120404 1.35 2729.22 - 
      
BU 4.361 426416 1.19 4421.79 9.54 
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• Preparation of samples for Assay 
• Preparation of Standard stock solution 
• Preparation of working standard solution 
• Preparation of Test stock solution 
• Preparation of working standard solution 
Calculation 
The amount of Budesonide and Formoterol Fumarate present in the formulation by 
using the formula given below, and results shown in a below table: 
 
Where, 
 
AS: Average peak area due to standard preparation 
AT: Peak area due to assay preparation 
WS: Weight of Budesonide / Formoterol Fumarate in mg 
WT: Weight of sample in assay preparation 
DT: Dilution of assay preparation 
 
 
Fig.6.10: Chromatogram of sample solution for Assay 
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Fig.6 11: Chromatogram of standard solution for Assay 
 
Table 6.12: Results of FF and BU (Standard) for Assay 
 
Drug RT (min) Peak Area TF Efficiency Resolution 
      
FF 2.114 118059 1.40 3502.30 - 
      
BU 4.528 424907 1.20 4222.64 9.53 
      
 
 
Table 6.13: Results of assay from tablet dosage form 
 
Drug Label claim(mg) Amount found(mg) % Assay 
    
FF 0.006 0.0058 98.05 
    
BU 0.4 0.3986 99.65 
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Observation: 
 
From chromatograms of sample solution , it was observed that the sample peaks 
found to be without any interference and% Assay of FF was found to be 98.05 % and  
Assay of BU was found to be 99.65 % .It was concluded that the % Assay was within 
the limits (98 % - 102 %). 
 
6.5. VALIDATION OF HPLC FOR METHOD DEVELOPMENT 
 
6.5.1. System suitability 
 
Standard solutions were prepared as per the test method and injected into the 
chromatographic system. The system suitability parameters like theoretical plates, 
resolution and asymmetric factor were evaluated. 
Table 6.14: Results for system suitability of 
FormoterolFumarate 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Injection RT(min) Peak area TP TR 
1 2.095 127651 1564.31 1.29 
2 2.095 127376 1634.55 1.31 
3 2.095 128904 1563.37 1.31 
4 2.096 126372 1612.78 1.29 
5 2.096 128143 1560.59 1.31 
6 2.098 127305 1624.48 1.29 
Mean  127625 -- -- 
SD  853.0 -- -- 
%RSD  0.7 -- -- 
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Table 6.15:Results for system suitability of Budesonide 
Injection RT(min) Peak area TP TF 
1 4.337 434309 4325.32 1.18 
2 4.344 436839 4242.75 1.18 
3 4.346 436814 4282.56 1.18 
4 4.348 435350 4384.18 1.18 
5 4.353 435462 4322.24 1.18 
6 4.354 439095 4348.18 1.19 
Mean  436311.4 - - 
SD  1669.5 - - 
%RSD  0.4 - - 
 
 
Acceptance criteria 
 
The % RSD for the retention times of Formoterol Fumarateand Budesonide Peaks  
from 6 replicate injections of each Standard solution should be not more than 2.0 % 
The number of theoretical plates (N) for the Formoterol Fumarate and Budesonide 
peaks is not less than 2000. 
 
The Tailing factor (T) for the Formoterol Fumarate and Budesonide peak is not more 
than 2.0. 
Observation: 
 
The % RSD for the retention times and peak area of Formoterol Fumarate and 
Budesonide were found to be less than 2%. The plate count and tailing factor results 
were found to be satisfactory and are found to be within the limit. 
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6.6 Specificity 
Preparation of blank solution. The Mobile phase, Potassium dihydrogen phosphate 
buffer pH - 4.5) :Acetonitrile (30:70) was taken as blank solution. 
 
 
Preparation of standard solution Tablet sample preparation 
 
The above prepared solutions were injected and the chromatograms were recorded for 
the same. The chromatogram for blank is shown figure 6.12.The chromatogram for 
the standard solution is given  in figure 6.14 and the results of the chromatogram are 
given the chromatogram for the test sample i.e tablet sample is given and the results 
of the chromatogram are given in figure 6.13. 
 
Fig. 6.12: Chromatogram of blank 
 
 
Fig. 6.13:Chromatogram for specificity of FF and BU sample 
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Fig. 6.14:Chromatogram for Specificity of FF and BUstandard 
 
 
Table.6.16: For Specificity of FormoterolFumarate and Budesonide sample 
 
 
Drug RT(min) Peak Area TF Efficiency Resolution 
      
FF 
2.093 120404 1.35 2729 
- 
  
      
BU 4.361 436416 1.19 4422 9.5 
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Table 6.17: Specificity of FormoterolFumarate and Budesonide standard 
 Retention     
Drug time (min) Peak Area TF Efficiency Resolution 
      
FF 
2.096 116063 1.40 2572 
- 
  
      
BU 4.356 428498 1.21 4211 9.2 
      
 
Observation: 
 
It was observed from the above data, diluent or excipient peaks are not interfering 
with the Formoterol Fumarate and Budesonide peaks. 
 
 Linearity and range 
 
Preparation of standard stock solution 
 
Preparation of working standard solution 
 
The working standard solution was prepared from the standard stock solution .The 
prepared working standard solutions were injected and the chromatograms were 
recorded for the same as shown in figures.6.15-6. 
 
From the obtained data, a graph between the concentration of the drug and peak area 
are plotted based on data given in figure .for Formoterol Fumarate and Budesonide 
respectively and the linearity graphs are given below 
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Table.6.18: Preparations for Linearity 
 
Preparations 
Volume from 
Standard  stock 
transferred  in 
ml 
Volume made 
up  in ml 
(with diluent) 
Concentration of 
solution(µg /ml) 
 
FORMO 
 
BUDESO 
Preparation 1 0.1 10 10   15 
Preparation 2 0.2 10 20 30 
Preparation 3 0.3 10 30 45 
Preparation 4 0.4 10 40 60 
Preparation 5 0.5 10 50 75 
 
 
 
Fig. 6.15: Chromatogram of Formoterol Fumarate and Budesonide preparation 1 
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Table: 6.19: Results of preparation-1 for Linearity 
 RT     
Drugss (min) Peak Area TF Efficiency Resolution 
      
FF 2.600 76879 1.29 2353.34 - 
      
B 5.745 72549 1.18 4293.09 9.75 
      
 
 
 
Fig. 6.16: Chromatogram of FormoterolFumarate and Budesonide preparation-2 
 
Table 6.20: Results of preparation-2 for Linearity 
Drugs 
Retention 
time (min) Area TF Efficiency Resolution 
FF 2.690 174699 1.36 2463.36 - 
BU 5.891 578153 1.21 4398.06 9.89 
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Fig. 6.17:ChromatogramFormoterolFumarate and Budesonide preparation-3 
 
Table 6.21: Results of preparation-3 for Linearity 
 
Drug RT (min) Peak Area TF Efficiency Resolution 
      
FF 2.726 110214 1.33 2376.70 - 
      
BU 6.019 384068 1.21 4557.69 9.94 
      
      
 
Fig. 6.18:Chromatogram of FormoterolFumarate and Budesonide preparation-4 
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Table. 6.22:Results of preparation-4 for Linearity 
 
Drug RT(min) Area TF Efficiency Resolution 
      
FF 2.740 233585 1.39 2440.18 - 
      
BU 6.030 726703 1.21 4407.77 9.86 
      
 
Fig. 6.19:Chromatogram Formoterol Fumarate and Budesonide preparation-5 
 
Table 6.23: Linearity data for preparation 5 
Drug RT (min) Peak Area TF Efficiency R esolution 
FF 2.800 344428 1.40 2434.75 - 
BU 6.176 1075106 1.22 4392.20 9.90 
 
 
Table 6.24: Results Linearity data of Formoterol Fumarate and Budesonide 
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S.NO. Conc(µg ) Area Conc(µg ) Area 
1. 15 76879 10 72549 
2. 30 174699 20 578153 
3. 45 110214 30 384068 
4. 60 233585 40 726703 
5. 75 344428 50 1075106 
 
 
Fig.6.20:Linearity graph of Formoterol Fumarate 
 
 
Fig.6.21: Linearity graph of Budesonide 
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Acceptance criteria 
 
The relationship between the concentration (in %) of Formoterol Fumarate 
and Budesonide and area of Formoterol Fumarate and Budesonide should be linear in 
the specified range and the correlation should not be less than 0.99. 
 
Observation 
 
The correlation coefficient for linear curve obtained between concentration vs. 
Area for standard preparations Formoterol Fumarate and Budesonide is 0.998 and 
0.996. The relationship between the concentration of Formoterol Fumarate and 
Budesonide and area of Formoterol Fumarate and Budesonide is linear in the range 
examined since all points lie in a straight line and the correlation coefficient is well 
within limits. 
 
 Accuracy 
 
Accuracy of the method was determined by Recovery studies. To the 
formulation (pre-analysed sample), the reference standards of the drugs were added at 
the level of 50%, 100%, 150%. The recovery studies were carried out three times and 
the percentage recovery and percentage mean recovery were calculated for drug is 
shown in table. To check the accuracy of the method, recovery studies were carried 
out by addition of standard drug solution to pre-analyzed sample solution at three 
different levels 50%, 100%, 150%. 
 
Preparation of standard stock solution (spikingPreparation of Test stock solution 
 
Preparation of sample solutions 
 
A. For preparation of 50% solution (with respect to target assay 
concentration) 
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5 mg of budesonide and 5 mg of Formoterol working standard were accurately 
weighed and transferred into a 10ml clean dry volumetric flask add about 2 ml of 
diluent and sonicate to dissolve it completely and make volume up to the mark with 
The same solvent (Stock Solution).Further pipette out 1 ml of the above stock 
solution into a 10ml volumetric flask and was diluted up to the mark with diluent. 
 
B. For preparation of 100% solution (with respect to target assay 
concentration) 
 
10 mg of budesonide and 10 mg of formoterolworking standards were accurately 
weighed and transferred into a 10ml clean dry volumetric flask add about 2 ml of 
diluent and sonicate to dissolve it completely and make volume up to the mark with 
the same solvent (Stock solution).Further pipette out 1 ml of above stock solution into 
a 10ml volumetric flask and was diluted up to the mark with diluent. 
 
C. For preparation of 150% solution (with respect to target assay 
concentration) 
 
15 mg of budesonide and 15 mg of formoterol working standards into a 10ml clean  
dry volumetric flask add about 2 ml of diluent and sonicate to dissolve it completely 
and make volume up to the mark with the same solvent. Further pipetteout 1 ml of the 
above stock solution into a 10ml volumetric flask and was diluted up to the mark with 
diluent. 
 
Procedure 
 
The standard solutions of accuracy 50%, 100% and 150%were injected into 
chromatographic system. Calculate the amount found and amount added for 
budesonide and Formoterol. Calculated the individual % recovery and mean %  
recovery values of each. 
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Procedure 
 
The standard solutions of accuracy 50%, 100% and 150%were injected into 
chromatographic system. Calculate the amount found and amount added for 
budesonide and formoteroland calculate the individual % recovery and mean % 
recovery values. 
 
For 50 % Recovery 
 
 
Fig. 6.22: Chromatogram of 50% recovery – injection 1 
 
 
Fig. 6.23: Chromatogram of 50% recovery – injection 2 
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Fig.6.24: Chromatogram of 50% recovery – injection 3 
 
Table 6.25:Results for 50% Recovery 
  FF  BU 
Injection       
       
 
RT 
 
Area RT 
 
Area 
       
1 2.655 
 
87403 5.781 
 
278081 
       
2 2.693 
 
88028 5.932 
 
285613 
       
3 2.664 
 
88863 5.835 
 
282085 
       
Avg 2.6706 
 
88098 5.849 
 
281926.33 
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For 100 % Recovery 
 
Fig. 6.25: Chromatogram of 100% recovery – injection 1 
 
 
Fig. 6.26: Chromatogram of 100% recovery – injection 2 
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Fig. 6.27:Chromatogram of 100% recovery – injection 3 
 
Table 6.26: Results for 100% Recovery 
 
  FF BU 
Injection 
 
RT Area  RT Area  
1 2.738 183067 5.897 552361 
2 2.387 151053 4.953 490353 
3 2.207 136633 4.556 469094 
 Avg 2.444 156917.66 5.135 503939.33 
 
For 150 % Recovery 
 
Fig. 6.28: Chromatogram of 150% recovery – injection 1  
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Fig. 6.29: Chromatogram of 150% recovery – injection 2 
 
 
 
Fig.6.30: Chromatogram of 100% recovery – injection 3 
 
 
Table 6.27: Results for 150% Recovery 
 
  FF  BU 
Injection       
       
 
RT Area RT 
 
Area 
       
1 2.148 196994 4.412  697285 
       
2 2.148 196994 4.412  697285 
       
3 2.435 235736 5.342  815472 
       
Avg 2.243 209908 4.722 
 
736680.666 
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Table 6.28:Results for Recovery of Formoterol Fumarate 
Concentration Area 
Amount 
added(µg
/ mL) 
Amount 
found(µg/ 
mL) 
% 
Recovery 
% mean 
Recovery 
50 88098 
50(µg/ 
mL) 49.26 98.52  
100 156917.66 
100(µg/ 
mL) 99.75 99.75 98.82 
150 209908 
150(µg/ 
mL) 147.38 98.2  
 
 
Table 6.29: Results for 150% Recovery 
 
Concentration Area 
Amount 
added(µg/ 
mL) 
Amount 
found(µg/ 
mL) 
% 
Recovery 
% mean 
Recovery 
50 281926 50(µg/ mL) 48.75 97.5  
100 503939 100(µg/ mL) 102.25 102.5 99.6 
150 736680 150(µg/ mL) 148.36 98.8 
 
 
 
Acceptance criteria 
 
The % recovery of Formoterol Fumarate and Budesonide should lie between 
98% and 102%. The RSD of all the recovery values should not be more than 2.0%. 
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Observation 
 
The percentage mean recovery of  Formoterol Fumarate and Budesonide is and 
respectively and the results were found to be within the limits. 
 
 
 Precision 
 
Precision was determined by analyzing standard  preparation of Formoterol Fumarate 
(50µg,ml) and Budesonide (2.5µgml) for six times. The chromatograms were 
recorded and the results were summarized in Table 6.30. 
 
Table 6.30: Results for Precision 
Injection Formoterol Fumarate Budesonide 
 
RT Area RT Area 
1 2.092 132443 4.327 436949 
2 2.093 130445 4.330 435877 
3 2.094 128713 4.331 431699 
4 2.094 128211 4.332 432385 
5 2.095 132105 4.333 433739 
6 2.096 126517 4.333 435272 
Average 
 
 1297389 
 
434319.9 
SD 
 
2331.2 
 
2058.8 
%RSD  1.8 
 
0.5 
 
Acceptance criteria 
 
The % Relative standard deviation of Peak area of Formoterol Fumarate and 
Budesonide from the six replicate injections should be not more than 2.0% 
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Observation 
 
Test results for Formoterol Fumarate and Budesonide are showing that the %RSD of 
Assay results are within limits. The results were shown in table 6.30. 
 Limit of Detection ( LOD) 
 
The following formula was used calculate LOD 
 
Where, 
σ = the standard deviation of the response 
 
 
S = the slope of the calibration curve 
 
The slope S may be estimated from the calibration curve of the analyte. 
 
The LOD for this method was found to be 0.655µg forFormoterolFumarate and 
1.201µg for Budesonide 
 
 Limit of Quatification 
 
 
Where, 
 
σ = the standard deviation of the response 
 
S = the slope of the calibration curve 
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The slope S may be estimated from the calibration curve of the analyte. 
 
The LOQ for this method was found to be 1.9 µg for Formotero l Fumarate and 3.642 
µg for Budesonide 
 
 Robustness 
 
Chromatographic conditions variation  
To demonstrate the robustness of the method, prepared standard solution as per test 
method and injected in 5 replicate at different variable conditions like using different 
conditions like flow rate and  temperature, wavelength, mobile phase organic 
composition. There was no significant change in the parameters like resolution, tailing 
factor, asymmetric factor, and plate count. System suitability parameters were 
compared with that of method precision. 
 
Acceptance criteria 
 
The system suitability should pass as per the test method at variable conditions. 
 
• Variation in flow 
 
 
Fig. 6.31:Chromatogram of FF and BU for Robustness(Less flow 0.8 mL/min) 
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Table 6.31:Results of Formoterol Fumarate and Budesonide for Robustness 
(0.8ml/min) 
 
Drug RT(min) Peak Area TF Efficiency Resolution 
      
     
- 
FF 3.015 197661 1.40 2436.50 
 
      
     
10.08 
BU 6.607 625443 1.21 4740.46 
 
      
 
 
Fig. 6.32:Chromatogram of FormoterolFumarate and Budesonide for Robustness 
(More flow 1.2 mL/min) 
 
Table 6.32: Results of FormoterolFumarate and Budesonide for Robustness (1.2 
mL/min) 
 
Drug RT (min) Peak area TF Efficiency Resolution 
FF 2.013 118857 1.35 2750.35 -- 
BU 4.098 413383 1.21 44983 9031 
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• Variation in Wave Length 
 
Fig. 6.33: Chromatogram ofFormoterolFumarate and Budesonide for 
Robustness (226nm) 
 
Table 6.33:ResultsofFormoterolFumarate and Budesonide for Robustness (226 nm) 
Drug RT (min) Peak Area TF Efficiency Resolution 
 
      
FF 2.034 133805 1.19 1708 - 
      
BU 3.511 483920 1.21 3721 6.7 
      
 
 
Fig.6.34:ChromatogramofFormoterolFumarate and Budesonide for Robustness 
(230nm) 
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Table.6.34:Results of Formoterol Fumarate and Budesonide for Robustness (230nm) 
Drug RT (min) Peak Area TF Efficiency Resolution 
FF 2.013 118857 1.35 2750.35 - 
BU 4.098 413383 1.21 4454.13 9.31 
 
 
Variation of mobile phase organic composition 
 
Fig. 6.35:Chromatogram of Formoterol Fumarate and Budesonide for robustness less 
organic 
 
Table 6.35:Results ofFormoterolFumarate and Budesonide for Robustness (less 
organic) 
Drug RT (min) Peak Area TF Efficiency 
Resolution 
- 
FF 2.705 166234 1.28 1624.81 - 
BU 6.985 527144 1.15 6001.97 13.38 
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Fig. 6.36:Chromatogram of FormoterolFumarate and Budesonide forRobustness(More 
Organic) 
 
Table 6.36: Summary Result of  Robustness study 
 
 
Formoterol 
Fumarate (FF) Budesonide (BU) 
Parameter 
    
RT(min) TF RT(min) TF  
     
Flow Rate     
0.8 mL/min 3.015 1.40 6.607 1.21 
1.0 mL/min 2.051 1.17 4.234 1.21 
1.2 mL/min 2.013 1.35 4.098 1.21 
     
 
Wavelength     
226 nm 2.034 1.19 3.511 1.32 
228 nm 2.051 1.17 4.234 1.21 
230 nm 2.013 1.35 4.098 1.21 
     
Mobile Phase     
Less organic(55% ) peak 2.705 1.28 6.985 1.85 
Area     
organic (50%) peak 2.051 1.17 4.234 1.21 
Area     
More organic (65%) 2.519 1.49 3.885 1.31S 
peak area     
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Observation 
 
From the results of robustness performed variations in flow rate and 
wavelength and composition of  Mobile phase . It was observed that not much 
variation in tailing factor was observed with deliberate changes in flow rate and 
wavelength and composition of mobile phase. The tailing factor was found to be 
within the limits for Formoterol Fumarate and Budesonide. 
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7. SUMMARY AND CONCLUSION 
    
 From the above observation data of the present research work related to new 
method development of Formoterol Fumarate and Budesonide was found satisfactory, 
simple, precise, accurate with good resolution, shorter retention time and among the 
other degradation products both Formoterol Fumarate and Budesonide were well 
separated with all accurate results. Low limit of quantization and limit of detection 
makes this method suitable for use in quality control. The less retention time obtained 
for the both drugs which reduces the run time enhances the usage of this method. 
 
 This is the first reported method for stability indicting simultaneous 
quantitative analysis of Formoterol Fumarate and Budesonide, and is a significant 
advance in chromatographic analysis of such pharmaceutical mixtures.. Forced 
degradation study results have shown good separation from degradation peaks. Hence 
we can clearly say that the proposed method is Economic, stable and truly novel 
validated method than the other reported methods 
 
 In the present developed method the acceptable validation parameters makes 
this method of analysis more acceptable for the routine analysis in quality control 
department in industries. Approved testing laboratories, bio-pharmaceutical and bio-
equivalence studies and in clinical pharmacokinetic studies. 
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